Darbepoetin alfa: new preparation. Just a me-too: no advantage in anaemia of chronic renal failure.
(1) Darbepoetin alfa, an epoetin, is slightly more glycosylated than epoetin alfa and beta. (2) The clinical file on anaemic patients with chronic kidney failure shows no advantage of darbepoetin alfa over other epoetins in terms of efficacy or side effects (subcutaneous injections of darbepoetin alfa are more often painful). (3) The dosing schedules of epoetins have not been compared adequately. Dosing schedules should be adapted for each patient.
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D016896:Treatment Outcome
D004921:Erythropoietin